N-acetylcysteine is effective for prevention but not for treatment of folic acid-induced acute kidney injury in mice

Critical Care Medicine

Volumn 39, Issue 11, 2011, Pages 2487-2494

  Wang, Hong Zhi ^b   Peng, Zhi Yong ^a   Wen, Xiao Yan ^a   Rimmelé, Thomas ^a   Bishop, Jeffery V ^a   Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

glutathione; N acetylcsteine; oxidative; renal

Indexed keywords

ACETYLCYSTEINE; CREATININE; CYSTATIN C; FOLIC ACID; GLUTATHIONE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; HISTOLOGY; INJURY SEVERITY; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 80054881440     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822575fc     Document Type: Article

References (41)

1. Liangos O, Wald R, O'Bell JW, et al: Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin J Am Soc Nephrol 2006; 1:43-51
2. Uchino S, Kellum JA, Bellomo R, et al: Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813-818 (Pubitemid 41175724)
3. Hoste EA, Clermont G, Kersten A, et al: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit Care 2006; 10:R73
4. Bagshaw SM, George C, Dinu I, et al: A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1203-1210 (Pubitemid 351767483)
5. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843 (Pubitemid 47220356)
6. Neveu H, Kleinknecht D, Brivet F, et al: Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996; 11:293-299 (Pubitemid 26063074)
7. Silvester W, Bellomo R, Cole L: Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med 2001; 29:1910-1915 (Pubitemid 32980400)
8. Bagshaw SM, Laupland KB, Doig CJ, et al: Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: A population-based study. Crit Care 2005; 9:R700-709
9. Mehta RL, Pascual MT, Soroko S, et al: Program to Improve Care in Acute Renal Disease. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 2004; 66:1613-1621 (Pubitemid 39298397)
10. Pannu N, Nadim MK: An overview of druginduced acute kidney injury. Crit Care Med 2008; 36(Suppl):S216-223 (Pubitemid 351483055)
11. Venkataraman R: Can we prevent acute kidney injury? Crit Care Med 2008; 36(Suppl): S166-171 (Pubitemid 351483047)
12. Nath KA, Norby SM: Reactive oxygen species and acute renal failure. Am J Med. 2000; 109:665-678
13. Liu M, Grigoryev DN, Crow MT, et al: Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76:277-285
14. Di Giorno C, Pinheiro HS, Heinke T, et al: Beneficial effect of N-acetyl-cysteine on renal injury triggered by ischemia and reperfusion. Transplant Proc 2006; 38:2774-2776 (Pubitemid 44737976)
15. Ali BH, Al-Salam S, Al-Husseini I, et al: Comparative protective effect of N-acetyl cysteine and tetramethylpyrazine in rats with gentamicin nephrotoxicity. J Appl Toxicol 2009; 29:302-307
16. Laisalmi-Kokki M, Personen E, Kokki H, et al: Potentially detrimental effects of N-acetylcysteine on renal function in knee arthroplasty. Free Radic Res 2009; 43:691-696
17. Sprong RC, Winkelhuyzen-Janssen AM, Aarsman CJ, et al: Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J Respir Crit Care Med 1998; 157: 1283-1293
18. Liu R, Nair D, Ix J, et al: N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005; 20:193-200 (Pubitemid 40626999)
19. Marenzi G, Assanelli E, Marana I, et al: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006 29; 354:2773-2782 (Pubitemid 43974195)
20. From AM, Bartholmai BJ, Williams AW, et al: Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: A retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol 2008; 3:10-18
21. Castini D, Lucreziotti S, Bosotti L, et al: Prevention of contrast-induced nephropathy: A single center randomized study. Clin Cardiol 2010 2; 33:E63-E68
22. Mullin EM, Bonar RA, Kane RD, et al: Reduction of folic acid-induced acute tubular injury by diuresis: An experimental model. Exp Mol Pathol 1976; 25:99-105
23. Yuan HT, Li XZ, Pitera JE, et al: Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxiainducible factor-1 alpha. Am J Pathol 2003; 163:2289-2301 (Pubitemid 37466473)
24. Long DA, Woolf AS, Suda T, et al: Increased renal angiopoietin-1 expression in folic acidinduced nephrotoxicity in mice. J Am Soc Nephrol 2001; 12:2721-2731 (Pubitemid 33115419)
25. Wang B, Navath RS, Romero R, et al: Antiinflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells. Int J Pharm 2009; 377:159-168
26. Wuyts WA, Vanaudenaerde BM, Dupont LJ, et al: N-acetylcysteine inhibits interleukin-17-induced interleukin-8 production from human airway smooth muscle cells: A possible role for anti-oxidative treatment in chronic lung rejection? J Heart Lung Transplant 2004; 23:122-127 (Pubitemid 38084838)
27. Cotgreave IA, Moldéus P: Methodologies for the analysis of reduced and oxidized N-acetylcysteine in biological systems. Biopharm Drug Dispos 1987; 8:365-375 (Pubitemid 17114983)
28. Thiele H, Hildebrand L, Schirdewahn C, et al: Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction NACC) Trial. J Am Coll Cardiol 2010; 55: 2201-2209
29. Muñoz AM, Rey P, Soto-Otero R, et al: Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J Neurosci Res 2004; 15:76:551-562 (Pubitemid 38580470)
30. Orrell RW, Lane JM, Ross MA: Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004; 18:CD002829
31. Hilmi IA, Peng Z, Planinsic RM, et al: N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant 2010; 25: 2328-2333
32. Millea PJ: N-acetylcysteine: Multiple clinical applications. Am Fam Physician 2009; 80: 265-269
33. Park JW, Floyd RA: Generation of strand breaks and formation of 8-hydroxy-2-deoxyguanosine in DNA by a thiol/Fe3+/O2-catalyzed oxidation system. Arch Biochem Biophys 1994; 312:285-291
34. Winterbourn CC: Hydroxyl radical production in body fluids. Roles of metal ions, ascorbate and superoxide. Biochem J 1981; 198:125-131 (Pubitemid 11063361)
35. Halliwell B, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990; 186:1-85 (Pubitemid 20279941)
36. Biemond P, van Eijk HG, Swaak AJ, et al: Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J Clin Invest 1984; 73: 1576-1579 (Pubitemid 14084473)
37. Molnár Z, Shearer E, Lowe D: N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: A prospective, randomized, placebo-controlled study. Crit Care Med 1999; 27:1100-1104 (Pubitemid 29314318)
38. Spapen HD, Diltoer MW, Nguyen DN, et al: Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: Results of a pilot study. Chest 2005; 127: 1413-1419 (Pubitemid 46224308)
39. Childs A, Jacobs C, Kaminski T, et al: Supplementation with vitamin C and N-acetylcysteine increases oxidative stress in humans. Free Radic Biol Med 2001;31: 745-753
40. Kimmel M, Butscheid M, Brenner S, et al: Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc-Preliminary results. Nephrol Dial Transplant 2008; 23: 1241-1245 (Pubitemid 351767504)
41. Hoffmann U, Fischereder M, Krüger B, et al: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-410. (Pubitemid 38140781)